SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2016
Aerie Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Commission File Number)|| |
2030 Main Street, Suite 1500
Irvine, California 92614
(Address of principal executive offices) (Zip code)
Registrants telephone number, including area code: (949) 526-8700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 5.07||Submission of Matters to a Vote of Security Holders.|
At the 2016 Annual Meeting of Stockholders of Aerie Pharmaceuticals, Inc. (the Company), held on June 8, 2016, the Companys stockholders (1) elected the persons listed below as directors to serve on the Board of Directors for a three-year term and (2) ratified the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016.
The table below sets forth the number of votes cast for, against or withheld, and the number of abstentions and broker non-votes, as applicable, for each matter voted upon by the Companys stockholders.
|Votes For||Votes Withheld||Broker Non-Votes|
Proposal 1: Election of Directors
Gerald D. Cagle, Ph.D.
|Votes For||Votes Against||Abstentions||Broker Non-Votes|
Proposal 2: Ratification of Appointment of
PricewaterhouseCoopers LLP as Independent
Registered Public Accounting Firm
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|AERIE PHARMACEUTICALS, INC.|
|Date: June 9, 2016||By:|| |
/s/ Richard J. Rubino
|Richard J. Rubino|
|Chief Financial Officer and Secretary|